AstraZeneca bladder cancer therapy wins NICE backing - PharmaTimes Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease

#AstraZeneca #bladdercancer #NICE #NICErecommended #durvalumab #perioperativeIOtreatment #perioperativeimmuneoncologytreatment #muscleinvasivebladdercancer #Niagaraphase3trial #bladdercancerpatients #innovativemedicine #JeannieRigby #bladdercancercare #perioperativeDurvalumab
zurl.co/U8lNl